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Background and Purpose: Inflammatory bowel disease (IBD) associates with 
damage to the enteric nervous system (ENS) leading to gastrointestinal (GI) 
dysfunction. Oxidative stress is important for the pathophysiology of inflammation-
induced enteric neuropathy and GI dysfunction. Apurinic/Apyrimidinic Endonuclease 
1/Redox Factor-1 (APE1/Ref-1) is a dual functioning protein that is an essential 
regulator of the cellular response to oxidative stress. In this study, we aimed to 
determine whether an APE1/Ref-1 redox domain inhibitor, APX3330 alleviates 
inflammation-induced oxidative stress that leads to enteric neuropathy in the Winnie 
murine model of spontaneous chronic colitis. 
Experimental Approach: Winnie mice received APX3330 or vehicle via 
intraperitoneal injections over two weeks and were compared to C57BL/6 controls. In 
vivo disease activity and GI transit were evaluated. Ex vivo experiments were 
performed to assess functional parameters of colonic motility, immune cell infiltration, 
and changes to the ENS.  
Key Results: Targeting APE1/Ref-1 redox activity with APX3330 improved disease 
severity, reduced immune cell infiltration, restored GI function and provided 
neuroprotective effects to the enteric nervous system. Inhibition of APE1/Ref-1 redox 
signalling leading to reduced mitochondrial superoxide production, oxidative DNA 
damage and translocation of high mobility group box 1 protein (HMGB1) were involved 
in neuroprotective effects of APX3330 in enteric neurons.  
Conclusion and Implications: This study is the first to investigate inhibition of 
APE1/Ref-1’s redox activity via APX3330 in an animal model of chronic intestinal 
 4 
inflammation. Inhibition of the redox function of APE1/Ref-1 is a novel strategy that 
might lead to a possible application of APX3330 for the treatment of IBD. 
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Inflammatory Bowel Disease (IBD) is defined by chronic, recurrent inflammation of the 
gastrointestinal (GI) tract, characterised by periods of remission and relapses. It is 
estimated that more than 5 million people globally suffer from IBD (Burisch and 
Munkholm 2015). IBD encompasses two major chronic idiopathic conditions, 
ulcerative colitis (UC) and Crohn’s disease (CD). UC is confined to the rectum and 
colon, where it is characterised by mucosal and submucosal ulcerations. In 
comparison, CD is transmural and displays skip lesions throughout the GI tract 
resulting in strictures or fistulas (Chang et al. 2015). IBD is a complex, multifactorial 
disorder with the exact cause being ambiguous. Current treatments are limited by their 
inefficacy and toxic side-effects.  Most present treatments focus on reducing clinical 
symptoms and do not exploit the pathogenic mechanisms of the disease, therefore, 
targeting pathophysiological mechanisms including enteric neuropathy may lead to 
more effective treatments.  
The enteric nervous system (ENS) consists of networks of intrinsic neurons embedded 
in the wall of the GI tract and controls GI functions with little assistance from the central 
nervous system (de Jonge 2013). Damage to the ENS is associated with GI 
dysfunction (Lakhan and Kirchgessner 2010; Lomax et al. 2005). The ENS has a vital 
role in GI immunity as interactions between enteric neurons and immune cells are 
important in both normal and pathological conditions (Knowles et al. 2013). Intestinal 
inflammation-induced ENS damage associates with a compromised GI antioxidant 
capacity (Brown and Gulbransen 2017) .  
Investigating oxidative stress in inflammatory conditions will provide insight into the 
pathogenesis of IBD and help to develop new therapies. Exposure of enteric neurons 
to oxidative stress results in disruption of physiological functions (Bagyánszki and Bódi 
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2012). Colon biopsies from IBD patients have shown increased levels of nitric oxide 
(NO) and oxidative stress induced DNA damage measured with a specific marker, 8-
hydroxydeoxyguanosine (8-OHdG) (D'Incà et al. 2006; Keshavarzian et al. 2003).  
APE1/Ref-1 is a vital dual functioning protein which regulates the cellular response to 
oxidative stress and acts as a DNA repair protein (Shah et al. 2017; Tell et al. 2009). 
The redox active domain of APE1/Ref-1 regulates cellular stress responses, 
angiogenesis, inflammation, and proliferation (Kelley et al. 2012; Kelley et al. 2014). 
In contrast, its endonuclease repair domain associates with DNA repair (Fishel et al. 
2008; Luo et al. 2008; Shah et al. 2017; Vascotto et al. 2009). Multiple inflammatory 
conditions produce oxidative stress resulting in altered APE1/Ref-1 responses; without 
interception by redox activation, cell apoptosis and carcinogenesis are likely (Liu et al. 
2017). Previous studies have demonstrated increased APE1/Ref-1 redox activity in 
tissues removed from IBD patients with active inflammation, indicating underlying 
oxidative stress within the GI tract (Hofseth et al. 2003; Lih-Brody et al. 1996). In 
addition, increased expression of APE1/Ref-1 was observed in colon sections from 
rats with dextran sodium sulfate (DSS)-induced colitis, which has been associated with 
an enhanced pro-inflammatory response (Chang et al. 2013). Thus, APE1/Ref-1 is 
involved in the pathophysiology of GI inflammation. Furthermore, APE1/Ref-1 
endonuclease activity protects dorsal root ganglion (DRG) neurons from inflammation 
and chemotherapy induced oxidative stress and DNA damage (Fehrenbacher et al. 
2017; Kelley and Fehrenbacher 2017). 
In this study we investigated the APE1/Ref-1 redox domain inhibitor, APX3330, as a 
potential therapeutic agent for treatment of chronic colitis and inflammation-induced 
enteric neuropathy using the Winnie murine model of spontaneous chronic colitis. In 
Winnie mice, spontaneous colitis develops from a primary intestinal epithelial defect 
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conferred by a mutation in the Muc2 mucin gene leading to intestinal inflammation at 
5-6 weeks of age progressing to severe colitis by the age of 12-16 weeks. This model 
closely represents pathophysiological mechanisms and clinical manifestations of 
human IBD (Eri et al. 2010; Heazlewood et al. 2008; Rahman et al. 2015; Robinson et 







Male and female Winnie mice (12 w.o; 20-30 g; n=24) were obtained from the Victoria 
University Werribee Animal Facility (Melbourne, Australia). Male and female C57BL/6 
mice (12 w.o; 20-30 g; n=12) were obtained from the Animal Resources Centre (Perth, 
Australia) and were used as controls. All mice were acclimatized for 3 days prior to 
receiving their allocated treatments. All mice were housed at the Western Centre for 
Health, Research and Education (Melbourne, Victoria, Australia) in a temperature-
controlled environment at 22C with a 12-hour day/night cycle. All animals had free 
access to food and water. All experimental procedures in this study were conducted 
in agreement with the Australian National Health and Medical Research Council 
(NHMRC) guidelines and under animal ethics AEETH 13/001 and AEC 17/016 
approved by Victorian University Animal Experimentation Ethic Committee (AEEC). 
Administration of APX3330 
Winnie mice were randomly divided into 2 groups: APX3330-treated and sham-
treated. Winnie APX3330-treated mice received APX3330 (Kelley laboratory, 
Indianapolis, IN, USA) at a dose of 25mg/kg via i.p injections dissolved in cremophor 
(2%) (Sigma-Aldrich): ethanol (2%) in sterile water (96%) (30G needle, max volume 
200µL). The dose of APX3330, route of administration and vehicle solution were 
based on previous studies in mice (Fishel et al. 2019; Yang et al. 2018). Mice received 
the treatment over two weeks, twice daily with a 12 hour interval. Winnie sham-treated 
mice received the vehicle i.p injections of cremophor (2%) (Sigma-Aldrich): ethanol 
(2%) in sterile water (96%) (30G needle, max volume 200µL) according to the same 
regimen as the treatment group. 
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Disease Activity 
Disease activity in Winnie mice can be characterised by clinical signs including rectal 
prolapse, diarrhoea, changes in colon length and body weight (Eri et al. 2010; 
Heazlewood et al. 2008; Rahman et al. 2015; Rahman et al. 2016). Mice were 
monitored throughout the treatment period for clinical symptoms. Body weights were 
recorded daily over 14 day period and expressed as a percent of change from the 
body weight at the start of the treatment. Directly after culling on day 15 the whole 
colon was excised, and the length was measured to assess changes in colon 
morphology. Faecal water content was assessed by collection of fresh faecal samples 
at day 14 prior to culling for ex vivo motility experiments. Faecal samples were 
collected by placing each mouse in a separate sterile cage without bedding until the 
expulsion of the faecal mass. The samples were immediately weighed to record the 
wet weight then placed in an oven at +60C for 24 hours. Dry weight was recorded 
and the difference between the wet and dry weight (water content) was calculated as 
a percent of the wet weight. 
Assessment of intestinal inflammation 
Measurement of faecal lipocalin (Lcn)-2 was used as a non-invasive detection of anti-
inflammatory efficacy of APX3330 treatment (Robinson et al., 2017). Faecal samples 
collected on day 14 from C57BL/6 control, Winnie sham-treated and Winnie APX3330-
treated mice were reconstituted in PBS-0.1 % Tween 20 (100mg/mL) to form a 
homogenous faecal suspension. This was centrifuged for 10 minutes at 12000 RPM 
at 4°C. Lcn-2 levels were estimated in the faecal pellet supernatants using Mouse 
NGAL ELISA Kit Lcn-2 (Abcam 199083). All samples were run in duplicate for 
statistical value. A microplate reader capable of measuring absorbance at 450nm, with 
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the correction wavelength set at 540nm, was used to detect Lcn-2 protein (pg/mL) in 
the faecal pellet supernatant. 
Gastrointestinal transit 
GI transit was measured via a non-invasive radiological method in C57BL/6 control 
mice and APX3330-treated and sham-treated Winnie mice after completion of 
treatment on day 14 as previously described (Robinson et al., 2017). Briefly, C57BL/6 
control, Winnie sham-treated and Winnie APX3330-treated mice received barium 
sulfate as contrast (2.5mg/mL; maximum volume of 200µL; X-OPAQUE-HD), via oral 
gavage. Sequential x-rays were taken using HiRay Plus Porta610HF x-ray apparatus 
(JOC Corp, Kanagawa, Japan; 50kV, 0.3mAs, exposure time 60ms) immediately post 
barium sulfate administration (0min) and then every 10 minutes for the first hour, 
followed by every 20 minutes until expulsion of the first pellet with barium sulphate or 
a maximum of 4 hours. Images were processed through Fujifilm FCR Capsule XL11 
and analysed on eFilm 4.2.0 software. Parameters of GI transit were measured by 
time (mins) to determine contrast passing through whole GI tract (whole transit time), 
stomach to caecum (gastro-caecal transit time; GCTT), caecum retention time and 
leaving caecum to anus (colonic transit time; CTT). C57BL/6 control, APX3330-treated 
and sham-treated Winnie mice were culled on the following day (day 15) and tissues 
were collected for ex-vivo studies. 
Organ bath experiments for isolated colonic motility  
Whole colons were removed from C57BL/6 control, Winnie sham-treated and Winnie 
APX3330-treated mice in oxygenated physiological saline and ex vivo organ-bath 
colonic motility experiments were performed as described previously (McQuade et al. 
2016; Robinson et al. 2017; Swaminathan et al. 2016). Briefly, colons were positioned 
horizontally, cannulated at the oral and anal ends in an organ bath superfused with 
 11 
Kreb’s solution (composition in mM: NaCL 118, KCl 4.6, CaCl2 3.5, MgSO4 1.2, 
NAH2PO4 1, NaHCO3 25 and d-Glucose 11; bubbled with 95% O2 and 5% CO2) whilst 
maintained at a constant temperature of 37C. The oral cannula was connected to a 
reservoir containing Kreb’s solution that was adjusted to maintain intraluminal 
pressure (0 to +2cm H2O). The anal end was coupled to an outflow tube with a 
maximum backpressure of 2cm H2O. Colonic contractile activity was recorded by a 
video camera positioned above the organ bath. Tissues were left to equilibrate at 
constant intraluminal pressure for 30 minutes followed by two sequential 20 minute 
video recordings of colonic contractile activity. Videos were transposed into 
spatiotemporal maps with Scribble v2.0 software and were analysed by using 
MATLAB v2017a software to assess parameters of colonic motility. 
Tissue collections 
Distal colon tissues were harvested in oxygenated physiological saline, flushed clear 
of faecal content and cut along the mesenteric border. Tissues were pinned down with 
the mucosal side up in a Sylgard-lined Petri dish and fixed with Zamboni’s fixative (2% 
formaldehyde containing 0.2% picric acid) overnight at 4°C. The fixative was removed 
by a series of washes (3 x 10 minutes) with dimethyl sulfoxide (DMSO) (Sigma-Aldrich, 
Sydney, Australia) followed by 3 10 minute washes with phosphate buffered saline 
(PBS). For cross sections, distal colon tissues were pinned and fixed as above without 
stretching, then covered by 50:50 optimum cutting temperature (OCT) compound 
(Tissue Tek, CA, USA) and frozen in liquid nitrogen-cooled isopentane and OCT and 
stored at -80°C until cryo-sectioned (20µm) onto glass slides. For wholemount 
longitudinal muscle with attached myenteric plexus (LMMP) preparations, distal colon 
segments were stretched to maximum capacity without tearing, fixed and washed as 
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above. To expose the myenteric plexus, the mucosa, submucosa and circular muscle 
layers were removed prior to immunohistochemical labelling. 
Immunohistochemistry and Histology 
Immunohistochemistry was performed as previously described (Rahman et al. 2015). 
Cross sections and wholemount LMMP preparations were incubated for 1 h at room 
temperature in 10% normalised donkey serum (Merck Millipore, Australia).  
Preparations were then washed (2 x 5 mins) with PBS and incubated with primary 
antisera (Table 1) overnight at room temperature in an enclosed moist environment. 
Cross sections and LMMP preparations were washed with 1x PBS (3 x 10 minute) and 
incubated with fluorophore-conjugated secondary antisera Alexa Fluor 488, 594 or 
647 of the respective anti-host species (1:200; Jackson Immunoresearch, West 
Grove, USA) for 2 hours at room temperature.  All specimens were stained with 4’,6’-
diamindino-2-pheylindole dihydrochloride (DAPI) to label cell nuclei. Tissues were 
given 3 x 10 min final washes in PBS, mounted on glass slides and cover slipped with 
fluorescent mounting medium (DAKO, Australia).  
Tissues for histology were cryo-sectioned at 10μm, cleared and rehydrated in graded 
ethanol concentration. For standard hematoxylin and eosin stain (H&E) sections were 
immersed in histolene (3 x 4 minutes), 100% ethanol (2 minutes), 95% ethanol (2 
minutes), 70% ethanol (2 minutes), rinsed in Tap water (30 seconds), then in 
hematoxylin (Sigma-Aldrich) (1 minute), rinsed in tap water, immersed in Scott’s tap 
water (1 minute) and eosin (Sigma-Aldrich) (5 minutes), rinsed in tap water, immersed 
in 100% ethanol (2 x 1 minute) and histolene (4 minutes) and finally mounted on glass 
slides with DPX mounting media. A histological grading system was used to evaluate 
gross morphological damage from the following parameters: aberrant crypt 
architecture (score range: 0–3), changes to crypt length (0–3), crypt abscesses (0–3), 
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leukocyte infiltration (0–3), epithelial damage (0–3) and ulceration (0–3); average of 
three areas of 500 µm2 per section. Slides were imaged using an Olympus BX53 
microscope (Olympus Imaging, Sydney, Australia). All slides were coded, and analysis 
was performed blindly. 
 
Imaging and quantitative analysis 
Triple-labelled specimens were visualised and imaged via confocal microscopy (Nikon 
Eclipse Ti multichannel confocal laser scanning system, Nikon, Japan) using 
combinations of FITC, Alexa 594 and Alexa 647 filters (495nm, 559nm or 640.4nm 
excitation wavelength respectively). Images (1062 X 1062 pixels) were obtained with 
x20 (dry) or x40 and x60 (oil immersion) lenses. Immunoreactivity for CD45, -Tubulin, 
and APE1/Ref-1 was analysed in cross sections and quantified as a percent of the 
area with specific fluorescence relative to the total 2 mm² area of colonic mucosa. 
Images of 3 colon sections from each tissue sample were captured with a x20 
objective to quantify the average area of fluorescence. Immunoreactivity for GFAP, 
MitoSOX™ and APE1/Ref-1 in LMMP preparations was analysed in 5 randomly 
chosen myenteric ganglia. Fluorescence was measured as a percentage relative to 
the ganglion area, using ImageJ software (NIH, MD, USA).  All images for CD45, -
Tubulin, APE1/Ref-1, GFAP and MitoSOX™ were acquired with equal acquisition and 
exposure time conditions, calibrated to standard minimum baseline fluorescence and 
converted to binary for analysis of the number of fluorescent pixels per image 
(McQuade et al. 2016; Robinson et al. 2017). Data were normalised and presented as 
percentage due to the variability in different ganglia and colon sizes between groups. 
The number of myenteric neurons were counted within 10 randomly selected ganglia 
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(expressed as an average number of neurons per ganglion) and within randomly 
chosen 4 images per preparation at x20 magnification (total area 1mm2) (expressed 
as number of neurons per area). The number of neurons with translocation of HMGB1 
from the nuclei to the cytoplasm was quantified with the aid of the nuclei marker DAPI.  
LMMP preparations were co-labelled with MAP2 and 8-OHdG to identify oxidative 
stress-induced DNA damage within myenteric neurons. The number of myenteric 
neurons co-localised with 8-OHdG was quantified as a proportion of the total number 
of neurons within an average of 10 myenteric ganglia. Neurons were counted using 
the Cell Counter plug-in in ImageJ software. All slides were coded and images were 
analysed blindly.  
 
Superoxide production in the myenteric plexus 
MitoSOX™ Red M36008 (Invitrogen, Australia), was used to identify mitochondrial-
derived production of superoxide in the myenteric ganglia (McQuade et al. 2016). 
Briefly, freshly excised preparations of the distal colon from C57BL/6 control, Winnie 
sham-treated and Winnie APX3330-treated mice were dissected to expose the 
myenteric plexus. Samples were incubated with 5µM MitoSOX™ Red M36008 at 37ºC 
for 40 minutes. Tissues were washed with oxygenated Krebs solution and fixed with 
Zamboni’s fixative for 1 hour followed by PBS washes (3 x 10 minutes). Preparations 
were mounted on glass slides with DAKO fluorescent mounting medium for imaging. 
Images were captured as described above. Images were converted into binary and 
fluorescent areas were measured in arbitrary units relative to ganglion area using 




The data and statistical analysis comply with the recommendations on experimental 
design and analysis in pharmacology (Curtis et al. 2015). Data were assessed using 
one-way ANOVA with Tukey’s post hoc tests for multiple group comparison. Analyses 
were performed using Graph Pad Prism (Graph Pad Software Inc., CA, USA). Data 
are presented as mean ± standard error of the mean (SEM). Value differences were 
considered statistically significant at P<0.05.  
Results 
APX3330 treatment improved clinical symptoms in Winnie mice 
C57BL/6 control mice did not display any symptoms of inflammation; the signs of 
diarrhoea, rectal prolapse and bleeding were absent; all C57BL/6 mice produced firm 
pellets during the 14 day period. All Winnie mice had chronic diarrhoea prior to start 
of the treatments.  Winnie sham-treated mice had chronic diarrhoea throughout the 
whole treatment period; some mice had rectal prolapse evident as a rectal protrusion 
with oedema and bleeding (Figure 1A). Winnie APX3330-treated mice that had rectal 
prolapse at the start of the treatment demonstrated reduced rectal prolapse, oedema 
and bleeding by day 14 of the treatment regimen (Figure 1A). Colons were excised 
and their length was measured at day 15 (Figure 1B). Colons from Winnie sham-
treated mice had shorter lengths (75.73.2mm, P<0.01, n=5) than C57BL/6 control 
mice (90.43.8mm, n=5) and contained soft faecal masses (Figure 1B’). APX3330 
treatment did not improve the colon lengths (70.41.9mm, P<0.05, n=5), however the 
presence of hard faecal pellets was prominent similar to C57BL/6 control mice (Figure 
1B-B’). Faecal water content was used as a measure of diarrhoea. Fresh faecal pellets 
were collected on day 14 to assess water content. Winnie sham-treated mice had 
higher level of faecal water content (83.42.7%, P<0.0001, n=7) than C57BL/6 control 
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mice (57.30.6%, n=7) (Figure 1C). Conversely, faeces from Winnie APX3330-
treated mice had lower faecal water retention (73.22.1%, P<0.01, n=7) than Winnie 
sham-treated mice, but higher levels than C57BL/6 control mice (P<0.0001) (Figure 
1C). Haematoxylin and eosin staining was performed in colon cross sections to 
evaluate gross morphological alterations using parameters described in the Methods 
section (Figure 1D). Winnie sham-treated mice attained a higher histological score 
(8.91.4, P<0.0001, n=5) compared to C57BL/6 control mice (0.50.2, n=5) (Figure 
1D’). APX3330 treatment reduced histological score in Winnie mice (8.91.4, 
P<0.001, n=5). Body weights of C57BL/6 control, Winnie sham-treated and Winnie 
APX3330-treated mice were measured over the 14 day period (Figure 1E). Winnie 
sham-treated mice showed progressively decreasing body weight which was 
significantly different from day 6 until day 14 compared to C57BL/6 control mice 
(Figure 1E). Winnie APX3330-treated mice grow slowly, but not equally well to control 
C57BL/6 mice and weighed significantly more (99.81.0%, n=8) than Winnie sham-
treated mice at day 14 (93.31.8%, P<0.05, n=10) (Figure 1E). 
 
APX3330 treatment reduced inflammation in the colon 
A pan-leukocyte marker anti-CD45 antibody was used in colon cross sections to 
investigate whether APX3330 treatment reduced immune cell infiltration in the Winnie 
mice colons (Figure 2A). The density of CD45-IR cells quantified as a percent of the 
CD45-IR area relative to the total 2 mm² area of colonic mucosa was significantly 
higher in Winnie sham-treated mice (24.91.8%, n=5) than in C57BL/6 control 
(13.60.6%, P<0.01, n=5) and Winnie APX3330-treated (12.01.3%, P<0.01, n=5) 
mice (Figure 2B). Severity of intestinal inflammation was assessed by the presence 
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of rectal prolapse and Lipocalin-2 (Lcn-2) levels in the faeces. Lcn-2, also known as 
neutrophil gelatinase-associated lipocalin,  is a non-invasive highly sensitive and 
specific biomarker for intestinal inflammation (Chassaing et al. 2012). At day 14, 
Winnie sham-treated mice displayed a higher faecal Lcn-2 level (462.4pg/mL, n=5) 
than C57BL/6 control mice (282.4pg/mL, P<0.001, n=5). Treatment with APX3330 
decreased faecal Lcn-2 levels (391.8pg/mL, P<0.01, n=5), although these were still 
greater than in C57BL/6 controls (Figure 2C). 
 
APX3330 treatment improved GI transit in Winnie mice 
The efficacy of APX3330 treatment was assessed on parameters of GI transit and 
colonic motility. Radiographic images captured movement of the contrast agent 
barium sulfate from the stomach to the rectum in C57BL/6 control (Figure 3A), Winnie 
sham-treated (Figure 3A’) and Winnie APX3330-treated (Figure 3A’’) mice. Total 
transit time in Winnie sham-treated (232.95.7mins, n=7) was longer than in C57BL/6 
control (174.311.1mins, P<0.01, n=7) mice. APX3330 treatment reduced the total 
transit time in Winnie mice (163.318.9mins, P<0.05, n=7) to a level comparable to 
C57BL/6 control mice (Figure 3B). No significant differences between experimental 
groups were observed in gastro-caecal transit time (GCTT) (Figure 3C), but other 
parameters of GI transit were compromised in Winnie sham-treated mice and restored 
in Winnie APX3330-treated mice. Winnie sham-treated mice had a prolonged contrast 
retention time in the caecum (165.79.7mins, n=7) compared to C57BL/6 control mice 
(93.612.8mins, P<0.01, n=7). But the caecum retention time in Winnie APX3330-
treated (86.417.8mins, P<0.01 compared to Winnie sham-treated group, n=7) was 
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similar to that of C57BL/6 control mice (Figure 3D). In contrary, colonic transit time 
(CTT) was shorter in Winnie sham-treated mice (18.62.6mins, n=7) than in C57BL/6 
control mice (40.85.2mins, P<0.01, n=7), but was restored to control levels in Winnie 
APX3330-treated (37.15.7mins, P<0.05 compared to Winnie sham-treated group, 
n=7) mice (Figure 3E).  
The effects of APX330 treatment on colonic contractile activity was assessed in ex 
vivo organ bath experiments (Figure 4). Colonic migrating motor complexes (CMMCs) 
are identified as contractions initiated from the oral end that propagated toward the 
anal end for >50% of the colon length (R. R. Roberts et al. 2008; Robinson et al. 2017). 
Video recordings were converted into spatiotemporal maps with contractions identified 
as orange/red lines (Figure 4A). Overall, the average length of colonic contractions in 
Winnie sham-treated mice (21.02.6%, n=6) was much shorter than in C57BL/6 
control mice (79.94.5%, P<0.0001, n=6). APX3330 treatment increased the length of 
colonic contractions (74.31.7%, P<0.0001, n=6) (Figure 4B). Lengths of CMMCs in 
Winnie sham-treated (50.27.2%, n=6) mice were significantly shorter than in 
C57BL/6 control mice (68.93.7%, P<0.05, n=6) (Figure 4C). Winnie APX3330-
treated mice had lengths of CMMCs (72.70.8%, P<0.05, n=6) similar to those of 
C57BL/6 control mice (Figure 4C). CMMCs were significantly faster in Winnie sham-
treated mice (average CMMC speed: 3.30.5mm/sec, n=6) than in C57BL/6 mice 
(2.00.1mm/sec, P<0.05, n=6). After APX3330 treatment, CMMC speed in Winnie 
mice (1.80.3mm/sec, n=6) was significantly slower than in Winnie sham-treated mice 
(P<0.05) and comparable to the speed of CMMCs in C57BL/6 mice (Figure 4D). 
CMMCs in Winnie sham-treated mice (4.01.0 CMMCs/10mins, n=6) were 
significantly less frequent than in C57BL/6 mice (8.00.5 CMMCs/10mins, P<0.05, 
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n=6). Treatment with APX3330 tended to increase the frequency of CMMCs (6.31.0 
CMMCs/10mins, n=6) compared to Winnie sham-treated mice, but significant 
difference was not achieved (Figure 4E). 
 
APX3330 treatment alleviated enteric neuropathy in Winnie mice 
An antibody specific to neuronal microtubule protein -tubulin (|||) was used to label 
nerve fibres in cross sections of the distal colon from C57BL/6 control, Winnie sham-
treated and Winnie APX3330-treated mice (Figure 5A). Winnie sham-treated mice 
had a significantly lower nerve fibre density in the distal colon (6.71.2%, P<0.001, 
n=5) than C57BL/6 control mice (14.41.2%, n=5) (Figure 5A, 5B), while APX3330 
treatment improved nerve fibre density in the colon (14.50.8, P<0.001, n=5) (Figure 
5A, 5B). 
Myenteric neurons were identified with a pan neuronal marker anti-MAP2 antibody in 
LMMP preparations from C57BL/6 control, Winnie sham-treated and Winnie 
APX3330-treated mice (Figure 5A). Fewer myenteric neurons per ganglion were 
observed in Winnie sham-treated mice (201 neurons, n=5) than in C57BL/6 control 
mice (374 neurons per ganglion, P<0.01, n=5) (Figure 5A, 5C). APX3330 treatment 
alleviated the loss of myenteric neurons in Winnie mice (323 neurons per ganglion, 
P<0.05 compared to Winnie sham-treated group, n=5) (Figure 5A, 5C). In Winnie 
sham-treated mice there were fewer myenteric neurons per unit area (18917 neurons 
per mm2, n=5) than in C57BL/6 control mice (34836 neurons per mm2, P<0.05, n=5) 
(Figure 5A, 5D). APX3330 treatment alleviated loss of myenteric neurons (32034 
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neurons per mm2, P<0.05, n=5) compared to Winnie sham-treated mice (Figure 5A, 
5D). 
Glial cell density was identified with an anti-GFAP antibody assessed in the myenteric 
plexus of the distal colon relative to the ganglion area in LMMP preparations from 
C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice (Figure 
5A). Winnie sham-treated mice had a significant decrease in glial cell density 
(15.60.6%, n=5) compared to C57BL/6 control mice (26.50.9%, P<0.01, n=5) 
(Figure 5A, 5E). APX3330 treatment of Winnie mice improved GFAP density 
(22.00.8%, P<0.01, n=5) when compared to Winnie sham-treated mice (Figure 5A, 
5E). 
 
APX3330 treatment reduced oxidative stress and associated DNA 
damage  
The fluorescent mitochondrial superoxide marker MitoSOX™ Red was used to 
evaluate superoxide production in distal colon myenteric ganglia from C57BL/6 
control, Winnie sham-treated, Winnie APX3330-treated mice (Figure 6A). High levels 
of MitoSOX™ fluorescence were evident in the myenteric plexus of Winnie sham-
treated mice (30.92.7%, P<0.05, n=5) when compared to C57BL/6 control mice 
(16.40.4%, n=5) (Figure 6A, 6B). Increased superoxide production in the myenteric 
plexus was alleviated in the colons from Winnie APX3330-treated mice (13.82.3%, 
P<0.01, n=5) (Figure 6A, 6B).  
Translocation of high mobility group box 1 (HMGB1) protein from nuclei to cytoplasm 
identifies its conversion to a damage associated molecular pattern (DAMP) that is 
released by dying cells to stimulate an immune response (Paudel et al., 2018). 
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HMGB1 translocation from neuronal nuclei to cytoplasm was analysed within LMMP 
preparations from C57BL/6 control, Winnie sham-treated and Winnie APX3330-
treated mice (Figure 6A’). In Winnie sham-treated mice many more cells exhibited 
HMGB1 translocation into the cytosol (173 neurons per ganglion, P<0.01, n=5) than 
in C57BL/6 control mice (00 neuron per ganglion, n=5) (Figure 6A’, 6C). APX3330 
treatment attenuated cytoplasmic translocation of HMGB1 in the myenteric ganglia 
(10 neuron per ganglion, P<0.05, n=5) compared to Winnie sham-treated mice 
(Figure 6A’, 6C). 
APE1/Ref-1 expression was determined by immunofluorescence within the myenteric 
plexus in the colon cross sections and LMMP preparations from C57BL/6 control, 
Winnie sham-treated and Winnie APX3330-treated mice (Figure 7A, 7A’). A 
significant increase in APE1/Ref-1 intensity was observed in the colon cross sections 
from Winnie sham-treated mice (32.23.3%, P<0.0001, n=5) compared to C57BL/6 
control mice (11.70.9%, n=5) (Figure 7A, 7B). APX3330 treatment reduced this 
overexpression of APE1/Ref-1 in colon cross sections (13.81.3%, P<0.001, n=5) 
compared to Winnie sham-treated mice (Figure 7A, 7B). The level of APE1/Ref-1 
immunoreactivity was increased within the myenteric ganglia of Winnie sham-treated 
mice (17.41.1%, P<0.05, n=5) compared to C57BL/6 control mice (11.81.5%, n=5) 
(Figure 7A’, 7C). In contrast, immunoreactivity in the myenteric ganglia from Winnie 
APX3330-treated mice (6.21.1%, P<0.001 compared to Winnie sham-treated group, 
n=5) was similar to C57BL/6 controls (Figure 7A’, 7C).  
Myenteric neurons were co-immunolabelled with a panneuronal marker, MAP2, and 
oxidative DNA damage marker, 8-OHdG (Figure 8A). Overall, 8-OHdG 
immunofluorescence density was significantly greater in Winnie sham-treated mice 
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(17.61.8%, P<0.01, n=5) than in C57BL/6 control mice (4.61.1%, n=5) (Figure 8A, 
8B). This immunoreactivity subsided in Winnie APX3330-treated mice (3.81.7%, 
P<0.01, n=5) to levels comparable to C57BL/6 control mice (Figure 8A, 8B). These 
results were consistent with the number of myenteric neurons colocalised with 8-
OHdG which was significantly larger in Winnie sham-treated mice (268.0%, P<0.01, 
n=5) than in C57BL/6 control mice (1.21.0%, n=5) (Figure 8A, 8C) or in Winnie 
APX3330-treated mice (1.90.8%, P<0.01 compared to Winnie sham-treated group, 
n=5) (Figure 8A, 8C). 
 
Discussion 
This is the first study to investigate the effects of APX3330, a small molecule inhibitor 
of APE1/Ref-1 redox signalling, in a clinically relevant animal model of IBD. Our study 
provides novel findings on the presence of APE1/Ref-1 in enteric neurons and 
increased level of APE1/Ref-1 in both the mucosa and myenteric ganglia, significant 
increase in mitochondrial ROS production, leading to oxidative DNA damage and 
translocation of HMGB1 in the colons from Winnie mice. Targeting this pathway with 
APX3330 ameliorated enteric neuropathy, colonic dysmotility and altered GI transit 
while providing anti-inflammatory and antioxidant effects in the Winnie murine model 
of spontaneous chronic colitis. These results demonstrate that APX3330 had 
prominent therapeutic effects in a preclinical animal model of IBD.  
The current treatments for IBD are limited due to inefficacy, intolerance, resistance, 
side-effects and inability to maintain remission (Ghadir et al. 2016; Nitzan et al. 2016). 
Frontline treatments tend to involve immunosuppression which has long-term 
detrimental effects leading to diminished quality of life in IBD patients (Abegunde et 
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al. 2016; Gionchetti et al. 2016; Hanauer 2016; Harris 2006). Several new biological 
treatments have been introduced into clinic that have helped to reduce use of 
corticosteroids, but many patients stop responding to the clinically approved drugs, so 
there is still a large unmet need for IBD treatment (Neurath 2017).  
Oxidative stress is a major contributing factor to tissue injury in IBD patients. Reduced 
mucosal antioxidant capacity and plasma antioxidants have been shown in patients 
with active CD and UC (Achitei et al. 2013; Ishihara et al. 2009; Lih-Brody et al. 1996). 
However, free radical antioxidants failed in clinical trials, as treatment with general 
antioxidants does not affect specific signalling and localized oxidative pathways or 
reversal of DNA damage within cells and subsequently within subcellular elements of 
cells (Aviello and Knaus, 2017). Therefore, new therapeutic strategies to block the 
major sources of oxidative stress are essential. Our study targeted a key molecule 
involved in oxidative DNA damage/repair mechanisms, APE1/Ref-1, which underpins 
cellular homeostasis and regulates multiple downstream inflammatory mediators that 
fuel uncontrolled homeostatic disbalance causing detrimental effects observed in IBD.  
APX3330 has the unique ability to suppress inflammation and chemotherapy-induced 
enhanced redox signalling activity of APE1/Ref-1 while providing neuroprotection in 
dorsal root ganglion neurons through an increase in oxidative DNA damage repair 
(Fehrenbacher et al. 2017; Kelley et al. 2016; Kim and Chang 2014; Kim et al. 2015).  
A recent phase I clinical trial of APX3330 in cancer patients demonstrated no 
significant toxicities/adverse effects, disease stabilization in six patients with four on 
drug for an extended time (252, 337, 357, and 421 days), predicted pharmacokinetics 
and target engagement (NCT03375086) (Chu et al. 2019; Shahda et al. 2019). Here 
we tested whether APX3330 alleviates intestinal inflammation, GI dysfunction and 
damage to enteric neurons in a pre-clinical model of spontaneous chronic colitis.   
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Rectal bleeding, prolapse, chronic diarrhoea, lack of body weight gain are clinical 
symptoms of chronic colitis in the Winnie mouse model (Eri et al. 2010; Heazlewood 
et al. 2008; Rahman et al. 2015; Rahman et al. 2016). Treatment with APX3330 
improved clinical signs associated with colonic inflammation in this model of chronic 
colitis. APX3330 attenuated rectal bleeding, improved stool consistency and 
prevented loss of body weight in Winnie mice.  Gross morphological damage of the 
colon demonstrated aberrant crypt architecture, crypt elongation, abscesses, epithelial 
damage and ulceration were prominent in Winnie sham-treated mice.  Increased 
colonic crypt length due to epithelial hyperplasia is consistently observed in Winnie 
mice with chronic colitis (Heaselwood et al., 2008; Eri et al. 2011; Rahman et al., 2015) 
as well in other models of chronic colitis (Erben et al 2014; Prattis and Jurjus, 2015), 
although in chemically-induced models of colitis (TNBS, DSS) both crypt elongation 
as well as crypt destruction with mucosal erosion have been reported (Fuss et al 2002; 
Jiminez et al 2015). These parameters of gross morphological damage were alleviated 
by APX3330 treatment. High levels of colonic leukocyte infiltration and faecal Lcn-2 
are reliable markers of inflammation which are prominent in multiple animal models of 
experimental colitis including Winnie mice (Rahman et al. 2015; Robinson et al. 2017). 
APX3330 alleviated the immune response in the Winnie mice after a two-week 
treatment regimen. This was shown by reduced CD45+ leukocyte infiltration 
throughout the distal colon and reduced levels of faecal Lcn-2 in Winnie APX3330-
treated mice.  Further studies need to be performed to define APX3330 effects on 
specific types of immune cells infiltrating the colon as well as specific inflammatory 
mediators.    
Winnie mice show an increase in total GI transit time due to a substantial delay in the 
caecum, although accelerated colonic transit is evident, consistent with previous 
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reports in this model (Robinson et al. 2017). Similarly, constipation in the proximal 
colon (James et al. 2018) and accelerated distal colonic transit (Haase et al. 2016; 
Rao et al. 1987) are common in patients with severe UC. Persistent alterations of GI 
transit in IBD patients and animal models beyond periods of acute inflammation 
indicate that damage to the intestinal innervation controlling GI functions is involved 
(Moynes et al. 2013). Intrinsic and extrinsic innervations are integral to the functions 
of the GI tract (Uesaka et al. 2016). Significant changes to intestinal transit result from 
modulation of the sympathetic and parasympathetic innervation of the GI tract 
observed in both Winnie and chemically-induced models of colitis (Lomax et al. 2005; 
Moynes et al. 2014; Rahman et al. 2015; Robinson et al. 2017). In addition to changes 
in GI transit time, there was a notable decrease in the average length of colonic 
contractions with a reduction in length, increased speed and lower frequency of 
CMMCs demonstrating distorted colonic motor activity in Winnie mice compared to 
controls. APX3330 treatment successfully restored total GI and colonic transit time in 
vivo as well as colonic CMMC lengths to control levels ex vivo. These changes 
correlate with increased colonic transit time observed in in vivo experiments. Although 
frequency of CMMCs has not returned to control levels, overall propulsive activities of 
the colon become more prominent. This positive modulation of the GI motility suggests 
that APX3330 treatment has direct or indirect effects on intestinal innervation. Whilst 
GI transit is influenced by both extrinsic and intrinsic neurons, the ex vivo contractile 
activity of the isolated colon is driven mainly by enteric neurons within the myenteric 
ganglia (Roberts et al. 2007). Accordingly, we focused on the mechanisms underlying 
these positive effects of APX3330 treatment in the myenteric plexus. 
Intestinal inflammation leads to enteric neuropathy resulting in compromised GI 
function (Mawe 2015; Moynes et al. 2013). The severity of inflammation in the colon 
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has an impact on myenteric neuronal loss in Winnie mice (Rahman et al. 2015). Loss 
of myenteric neurons and neuronal fibres occurs in multiple animal models of intestinal 
inflammation and in IBD patients (Bernardini et al. 2012; Boyer et al. 2005; Linden et 
al. 2005; Nurgali et al. 2007; Nurgali et al. 2011; Rahman et al. 2016). In addition, 
reduced expression of GFAP-positive glial cells within myenteric ganglia is seen in 
Winnie mice in this study. In contrast, studies of colonic biopsies from IBD patients, 
animal models of colitis and in vitro cultures yielded divergent results on the 
expression of GFAP in inflammatory conditions (Pochard et al. 2018). The reduced 
immunofluorescence density of GFAP-positive glial cells in our study may be due to 
either loss of GFAP-positive glial cells, phenotypic changes or decreased expression 
of the protein corresponding to a loss of glial reactivity.  Other types of glial cells should 
be considered in future studies of this model. Enteric glial cells regulate intestinal 
homeostasis and protect enteric neurons from oxidative stress-induced death (Abdo 
et al. 2009; Roberts et al. 2013). Loss of GFAP-positive glial cells causes degeneration 
of enteric neurons and intestinal inflammation (Bush et al., 1998; Cornet et al., 2001). 
Altered signalling between enteric glia and neurons contributes to colonic dysmotility 
(McClain et al., 2014). However, in inflammatory conditions, activated enteric glial cells 
mediate neuronal death via activation of purinergic signalling (Brown et al. 2016). 
Purinergic transmission plays an important role in both excitatory and inhibitory in 
neuronal pathways as well as sensory transduction in the ENS (Bornstein 2008). 
Purinergic signalling via P2 receptors plays an important role in controlling nuclear 
maintenance of APE1/Ref-1 (Pines et al. 2005). Activation of P2 receptors and 
intracellular ROS production cause APE1/Ref-1 translocation from the nucleus to 
cytoplasm (Pines et al. 2005) which was also observed in our study. The role of 
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purinergic signalling in regulation of APE1/Ref-1 function in various functional types of 
enteric neurons needs to be further elucidated. 
APX3330 treatment alleviated loss of myenteric neurons, improved nerve fibre and 
GFAP immunoreactivity in the myenteric ganglia when compared to Winnie sham-
treated mice. APX3330 has been proven to be neuroprotective in sensory neurons 
after insults caused by ionizing radiation, cheotherapeutic agents and inflammatory 
stimuli all producing oxidative DNA damage acted upon by APE1/Ref-1 (Fehrenbacher 
et al. 2017; Jiang et al. 2009; Kelley et al. 2014; Kim et al. 2015; Vasko et al. 2011). 
These studies showed that enhancement of the DNA repair function of APE1/Ref-1, 
but not its redox signalling, underlies neuroprotective effects of APX3330 in sensory 
neurons. This was demonstrated using both a genetic and small molecule approach 
with APX3330 (Jiang et al. 2009; Kelley et al. 2014; Kelley et al. 2016; Kim et al. 2015). 
Facilitation of the endonuclease activity of APE1/Ref-1 stimulates base excision repair 
(BER) of oxidative DNA damage in neurons (Kelley et al. 2014).  Our study provides 
novel findings on the presence of APE1/Ref-1 in enteric neurons and increased level 
of APE1/Ref-1 in both the mucosa and myenteric ganglia in the colons from Winnie 
mice. These results are consistent with findings in the colon tissues removed from IBD 
patients with active inflammation (Hofseth et al. 2003) and in the colonic epithelium of 
an animal model of DSS-induced colitis (Chang et al. 2013). Inflammation caused by 
pathogenic bacteria, ionising radiation, ROS and toxic agents transiently increase 
intracellular APE1/Ref-1 in gastric epithelial cells and sensory neurons (O’Hara et al. 
2006; Vasko et al. 2011). Our results indicate that APX3330 treatment alleviates the 
APE1/Ref-1 redox activity in Winnie mice after the two-week treatment regimen. As 
APX3330 regulates the inflammatory response, loss of enteric neurons and 
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immunoreactivity of GFAP in our model of IBD, we tested if these effects result from 
dysregulation of ROS production in the myenteric plexus. 
In the GI tract, the main sources of ROS are the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase enzymes (NOX and dual oxidase (DUOX)), NOS and 
the mitochondrial electron transport chain (mETC).  NOX and DUOX produce ROS 
not as a by-product, but as a primary function. GI tissues express multiple NOX 
isoforms, including NOX1, NOX2, NOX4 and DUOX2 within different cell types 
including macrophages, lymphocytes and neutrophils, epithelial cells, fibroblasts and 
glandular cells throughout the GI tract (Lam et al., 2015). Recent study demonstrated 
that enteric glial cells increase expression of NOX-2 in response to inflammatory 
stimuli (Kimono et al. 2019).  NOX expression in enteric neurons of the GI tract has 
not been investigated. It is known that mitochondria can regulate, activate, differentiate 
and aid survival of immune cells (Angajala et al. 2018). Deregulation of the 
mitochondrial electron transport chain (mETC), with increased mitochondrial ROS 
(mtROS) levels, was observed in IBD patients (Dashdorj et al. 2013). Oxidants 
produced by GI cells provide an antibacterial defence (Wink et al. 2011). Uncontrolled 
and persistent overproduction of ROS due to up‐regulation of oxidases or altered 
mitochondrial function and/or inadequate removal of ROS by antioxidant systems 
causes tissue injury and exacerbates inflammation eventually leading to other chronic 
complications, such as fibrosis, neoplasia and extra‐intestinal symptoms (Rezaie et 
al.2007; Aviello and Knaus, 2017). In addition, it has been shown that the production 
of ROS induces DNA damage leading to neuronal loss (Harrison et al. 2005).  In our 
study, oxidative stress in myenteric neurons and surrounding cells was shown by the 
increased mitochondrial superoxide production in Winnie mice. Myenteric neurons in 
Winnie mice exhibit increased mitochondrial superoxide and oxidative stress-induced 
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DNA damage, as seen in multiple studies that describe increase in oxidative DNA 
damage in the colonic mucosa of IBD patients (D'Incà et al. 2006; Dincer et al. 2007; 
Lih-Brody et al. 1996) and chemically-induced colitis (Chang et al. 2013). Our results 
demonstrate that APX3330 reduced oxidative stress via its redox inhibition of 
APE1/Ref-1 and oxidative DNA damage in chronic colitis. On the other hand, 
suppressing APE1/Ref-1’s redox activity with APX3330 enhances APE1/Ref-1’s 
endonuclease repair activity via the BER pathway which takes place in both the nuclei 
and mitochondria.  APE1/Ref-1’s endonuclease activity is responsible for repairing 
DNA damage induced by oxidative stress, alkylating agents, and ionising radiation 
(Krokan and Bjørås 2013; Shah et al. 2017). Further studies required to elucidate 
APE1/Ref-1’s endonuclease repair activity in enteric neurons after APX3330 
treatment.   
DNA damage can induce translocation of HMGB1 from the nucleus to the cytoplasm 
(Park et al. 2004; Tang et al. 2016; Tsung et al. 2007). Significantly higher numbers of 
cells in the myenteric plexus of Winnie mice displayed translocation of HMGB1 from 
the nucleus to the cytoplasm indicating cellular stress. HMGB1 has various functions 
which depend on its location outside or inside the cell. Acetylated cytosolic HMGB1 
released from cells into extracellular space acts as a proinflammatory mediator 
interacting with immune cells and stimulating production of cytokines and chemokines 
(Janko et al. 2014; Paudel et al. 2018) leading to neuroinflammation, hyperexcitability 
and neuronal death (Kaneko et al. 2017; Okuma et al. 2012). APE1/Ref-1  regulates 
the release of cytosolic HMGB1 and the inflammatory signalling to extracellular 
HMGB1 (Yuk et al. 2009). After APX3330 treatment HMGB1 was retained in the nuclei 
of myenteric neurons, thereby reducing release of HMGB1 and presumably increasing 
survival of colonic myenteric neurons in Winnie mice. This is consistent with findings 
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that nuclear HMGB1 directly interacts with and enhances the endonuclease activity of 
APE1/Ref-1 (Balliano et al. 2017) acting as a cofactor modulating BER capacity in 
cells (Prasad et al. 2007). 
 
Conclusion 
This study is the first to provide evidence for therapeutic effects of APX3330 in 
alleviating inflammatory responses, disease severity, GI dysfunction and enteric 
neuropathy. Inhibition of mitochondrial superoxide production, APE1/Ref-1 redox 
signalling, oxidative DNA damage and translocation of HMGB1 are some of the 
mechanisms involved in neuroprotective effects of APX3330 in enteric neurons 
(Figure 9).  Further studies are needed to elucidate more detailed molecular 
mechanisms underlying the role of APE1/Ref-1, its redox signalling and DNA 
damage/repair functions in enteric neurons as well as long term effects of APX3330 
treatment.  However, results of the recent clinical trial in oncology patients with 
advanced solid tumors demonstrated that long term treatment with APX3330 did not 
show any safety concerns (Chu et al. 2019; Shahda et al. 2019). Thus, specific 
inhibition of the redox signalling function of the APE1/Ref-1 molecule is a novel 
strategy that might lead to a possible application of APX3330 for the treatment of IBD 






Abdo, Hind, et al. (2009), 'Enteric glial cells protect neurons from oxidative stress in part via reduced 
glutathione', The FASEB Journal, 24 (4), 1082-94. 
Abegunde, Ayokunle T., Muhammad, Bashir H., and Ali, Tauseef (2016), 'Preventive health measures 
in inflammatory bowel disease', World Journal of Gastroenterology, 22 (34), 7625-44. 
Achitei, D., et al. (2013), 'Different Profile of Peripheral Antioxidant Enzymes and Lipid Peroxidation 
in Active and Non-active Inflammatory Bowel Disease Patients', Digestive Diseases and 
Sciences, 58 (5), 1244-49. 
Angajala, Anusha, et al. (2018), 'Diverse Roles of Mitochondria in Immune Responses: Novel Insights 
Into Immuno-Metabolism', Frontiers in immunology, 9, 1605-05. 
Aviello G, Knaus UG (2017), 'ROS in gastrointestinal inflammation: Rescue Or Sabotage?', Br J 
Pharmacol. 174(12), 1704‐1718. 
Bagyánszki, Mária and Bódi, Nikolett (2012), 'Diabetes-related alterations in the enteric nervous 
system and its microenvironment', World Journal of Diabetes, 3 (5), 80-93. 
Balliano, Angela, et al. (2017), 'HMGB1 Stimulates Activity of Polymerase β on Nucleosome 
Substrates', Biochemistry, 56 (4), 647-56. 
Bernardini, Nunzia, et al. (2012), 'Immunohistochemical analysis of myenteric ganglia and interstitial 
cells of Cajal in ulcerative colitis', Journal of cellular and molecular medicine, 16 (2), 318-27. 
Bornstein, J. C. (2008), 'Purinergic mechanisms in the control of gastrointestinal motility', Purinergic 
Signalling, 4 (3), 197-212. 
Boyer, L., et al. (2005), 'Myenteric plexus injury and apoptosis in experimental colitis', Auton 
Neurosci, 117 (1), 41-53. 
Brown, Isola A. M. and Gulbransen, Brian D. (2017), 'The antioxidant glutathione protects against 
enteric neuron death in situ, but its depletion is protective during colitis', American Journal 
of Physiology-Gastrointestinal and Liver Physiology, 314 (1), G39-G52. 
Brown, Isola A. M., et al. (2016), 'Enteric glia mediate neuron death in colitis through purinergic 
pathways that require connexin-43 and nitric oxide', Cellular and molecular gastroenterology 
and hepatology, 2 (1), 77-91. 
Burisch, Johan and Munkholm, Pia (2015), 'The epidemiology of inflammatory bowel disease', 
Scandinavian Journal of Gastroenterology, 50 (8), 942-51. 
Chang, Chen-Wang, et al. (2015), 'Intestinal Stricture in Crohn's Disease', Intestinal Research, 13 (1), 
19-26. 
Chang, In-Youb, et al. (2013), 'Apurinic/apyrimidinic endonuclease 1, the sensitive marker for DNA 
deterioration in dextran sulfate sodium-induced acute colitis', Redox Report, 18 (5), 165-73. 
Chassaing, Benoit, et al. (2012), 'Fecal Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive 
Biomarker for Intestinal Inflammation', PLOS ONE, 7 (9), e44328. 
Chu, Lincy, et al. (2019), 'CTC enumeration and characterization as a pharmacodynamic marker in 
the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced 
solid tumors', Journal of Clinical Oncology, 37 (15_suppl), e14531-e31. 
Curtis, Michael J., et al. (2015), 'Experimental design and analysis and their reporting: new guidance 
for publication in BJP', British Journal of Pharmacology, 172 (14), 3461-71. 
Dashdorj A, Jyothi KR, Lim S, Jo A, Nguyen MN, Ha J, et al. (2013), 'Mitochondria‐targeted 
antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 
inflammasome‐mediated inflammatory cytokines', BMC Med. 11: 178. 
D'Incà, Renata, et al. (2006), 'Oxidative DNA damage in the mucosa of ulcerative colitis increases 
with disease duration and dysplasia', Inflammatory Bowel Diseases, 10 (1), 23-27. 
de Jonge, Wouter J. (2013), 'The Gut's Little Brain in Control of Intestinal Immunity', ISRN 
Gastroenterology, 2013, 630159. 
Dincer, Yıldız, et al. (2007), 'Oxidative DNA Damage and Antioxidant Activity in Patients with 
Inflammatory Bowel Disease', Digestive Diseases and Sciences, 52 (7), 1636-41. 
 32 
Erben U, Loddenkemper C, Doerfel K, et al. (2014), 'A guide to histomorphological evaluation of 
intestinal inflammation in mouse models', Int J Clin Exp Pathol. 7(8), 4557‐4576.  
Eri, R. D., et al. (2011), 'An intestinal epithelial defect conferring ER stress results in inflammation 
involving both innate and adaptive immunity', Mucosal Immunology, 4, 354-364. 
Fehrenbacher, Jill C., et al. (2017), 'DNA damage mediates changes in neuronal sensitivity induced by 
the inflammatory mediators, MCP-1 and LPS, and can be reversed by enhancing the DNA 
repair function of APE1', Neuroscience, 366, 23-35. 
Fishel, Melissa L., et al. (2008), 'Knockdown of the DNA repair and redox signaling protein Ape1/Ref-
1 blocks ovarian cancer cell and tumor growth', DNA repair, 7 (2), 177-86. 
Fishel, Melissa L., et al. (2019), 'Anti-tumor activity and mechanistic characterization of APE1/Ref-1 
inhibitors in bladder cancer', Molecular Cancer Therapeutics, molcanther.1166.2018. 
Fuss IJ, Boirivant M, Lacy B, Strober W. (2002), 'The interrelated roles of TGF-beta and IL-10 in the 
regulation of experimental colitis', J Immunol. 168(2), 900‐908. 
Ghadir, Mohammad Reza, et al. (2016), 'Nonadherence to Medication in Inflammatory Bowel 
Disease: Rate and Reasons', Middle East Journal of Digestive Diseases, 8 (2), 116-21. 
Gionchetti, Paolo, et al. (2016), 'Use of corticosteroids and immunosuppressive drugs in 
inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of 
Inflammatory Bowel Disease', Digestive and Liver Disease, 49 (6), 604-17. 
Haase, A. M., et al. (2016), 'Regional gastrointestinal transit times in severe ulcerative colitis', 
Neurogastroenterology & Motility, 28 (2), 217-24. 
Hanauer, Stephen B. (2016), 'Oral or Topical 5-ASA in Ulcerative Colitis', Digestive Diseases (Basel, 
Switzerland), 34 (1-2), 122-24. 
Harris, Raymond C. (2006), 'COX-2 and the Kidney', Journal of Cardiovascular Pharmacology, 47. 
Harrison, Jason F., et al. (2005), 'Oxidative stress-induced apoptosis in neurons correlates with 
mitochondrial DNA base excision repair pathway imbalance', Nucleic acids research, 33 (14), 
4660-71. 
Heazlewood, Chad K., et al. (2008), 'Aberrant Mucin Assembly in Mice Causes Endoplasmic 
Reticulum Stress and Spontaneous Inflammation Resembling Ulcerative Colitis', PLOS 
Medicine, 5 (3), e54. 
Hofseth, Lorne J., et al. (2003), 'The adaptive imbalance in base excision–repair enzymes generates 
microsatellite instability in chronic inflammation', Journal of Clinical Investigation, 112 (12), 
1887-94. 
Ishihara, Tomoaki, et al. (2009), 'Therapeutic Effect of Lecithinized Superoxide Dismutase against 
Colitis', Journal of Pharmacology and Experimental Therapeutics, 328 (1), 152. 
James, Sally L., et al. (2018), 'Characterization of ulcerative colitis-associated constipation syndrome 
(proximal constipation)', JGH open : an open access journal of gastroenterology and 
hepatology, 2 (5), 217-22. 
Janko, Christina, et al. (2014), 'Redox modulation of HMGB1-related signaling', Antioxidants & redox 
signaling, 20 (7), 1075-85. 
Jiang, Yanlin, et al. (2009), 'Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response 
to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions', DNA 
repair, 8 (11), 1273-82. 
Jiminez JA, Uwiera TC, Douglas Inglis G, Uwiera RR. (2015), 'Animal models to study acute and 
chronic intestinal inflammation in mammals'. Gut Pathog. 7, 29. 
Kaneko, Y., et al. (2017), 'Extracellular HMGB1 Modulates Glutamate Metabolism Associated with 
Kainic Acid-Induced Epilepsy-Like Hyperactivity in Primary Rat Neural Cells', Cellular 
Physiology and Biochemistry, 41 (3), 947-59. 
Kelley, Mark R. and Fehrenbacher, Jill C. (2017), 'Challenges and opportunities identifying 
therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from 
oxidative DNA damage', Neural regeneration research, 12 (1), 72-74. 
 33 
Kelley, Mark R., Georgiadis, Millie M., and Fishel, Melissa L. (2012), 'APE1/Ref-1 Role in Redox 
Signaling: Translational Applications of Targeting the Redox Function of the DNA 
Repair/Redox Protein APE1/Ref-1', Current Molecular Pharmacology, 5 (1), 36-53. 
Kelley, Mark R., et al. (2014), 'Role of the DNA Base Excision Repair Protein, APE1 in Cisplatin, 
Oxaliplatin, or Carboplatin Induced Sensory Neuropathy', PLoS ONE, 9 (9), e106485. 
Kelley, Mark R., et al. (2016), 'Identification and Characterization of New Chemical Entities Targeting 
Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced 
Peripheral Neuropathy', The Journal of pharmacology and experimental therapeutics, 359 
(2), 300-09. 
Keshavarzian, A., et al. (2003), 'Increases in free radicals and cytoskeletal protein oxidation and 
nitration in the colon of patients with inflammatory bowel disease', Gut, 52 (5), 720-28. 
Kim, Eun Ran and Chang, Dong Kyung (2014), 'Colorectal cancer in inflammatory bowel disease: The 
risk, pathogenesis, prevention and diagnosis', World Journal of Gastroenterology : WJG, 20 
(29), 9872-81. 
Kim, Hyun-Suk, et al. (2015), 'APE1, the DNA base excision repair protein, regulates the removal of 
platinum adducts in sensory neuronal cultures by NER', Mutation research, 779, 96-104. 
Kimono D, Sarkar S, Albadrani M, et al. (2019), 'Dysbiosis-associated enteric glial cell immune-
activation and redox imbalance modulate tight junction protein expression in Gulf War illness 
pathology', Front Physiol. 10, 1229. 
Knowles, Charles H., et al. (2013), 'New perspectives in the diagnosis and management of enteric 
neuropathies', Nature Reviews Gastroenterology &Amp; Hepatology, 10, 206. 
Krokan, Hans E. and Bjørås, Magnar (2013), 'Base Excision Repair', Cold Spring Harbor Perspectives in 
Biology, 5 (4), a012583. 
Lakhan, Shaheen E. and Kirchgessner, Annette (2010), 'Neuroinflammation in inflammatory bowel 
disease', Journal of Neuroinflammation, 7 (1), 37. 
Lam G, Apostolopoulos V, Zulli A, and Nurgali K (2015), 'NADPH oxidases and inflammatory bowel 
disease', Curr Med Chem. 22(17), 2100‐2109. 
Lih-Brody, Lisa, et al. (1996), 'Increased oxidative stress and decreased antioxidant defenses in 
mucosa of inflammatory bowel disease', Digestive Diseases and Sciences, 41 (10), 2078-86. 
Linden, D. R., et al. (2005), 'Indiscriminate loss of myenteric neurones in the TNBS-inflamed guinea-
pig distal colon', Neurogastroenterol Motil, 17 (5), 751-60. 
Liu, Hao, et al. (2017), 'Redox Imbalance in the Development of Colorectal Cancer', Journal of Cancer, 
8 (9), 1586-97. 
Lomax, A. E., Fernández, E., and Sharkey, K. A. (2005), 'Plasticity of the enteric nervous system during 
intestinal inflammation', Neurogastroenterology & Motility, 17 (1), 4-15. 
Luo, Meihua, et al. (2008), 'Role of the Multifunctional DNA Repair and Redox Signaling Protein 
Ape1/Ref-1 in Cancer and Endothelial Cells: Small-Molecule Inhibition of the Redox Function 
of Ape1', Antioxidants & Redox Signaling, 10 (11), 1853-67. 
Mawe, Gary M. (2015), 'Colitis-induced neuroplasticity disrupts motility in the inflamed and post-
inflamed colon', The Journal of Clinical Investigation, 125 (3), 949-55. 
McQuade, Rachel M., et al. (2016), 'Role of oxidative stress in oxaliplatin‐induced enteric neuropathy 
and colonic dysmotility in mice', British Journal of Pharmacology, 173 (24), 3502-21. 
Moynes, Derek M., et al. (2013), 'Effects of Inflammation on the Innervation of the Colon', 
Toxicologic Pathology, 42 (1), 111-17. 
Moynes, Derek M.; Lucas, Graydon H.; Beyak, Michael J.;  and Lomax, Alan E. (2014), 'Effects of 
Inflammation on the Innervation of the Colon'. 
Neurath, M. F. (2017), 'Current and emerging therapeutic targets for IBD', Nat Rev Gastroenterol 
Hepatol, 14 (5), 269-78. 
Nitzan, Orna, et al. (2016), 'Role of antibiotics for treatment of inflammatory bowel disease', World 
Journal of Gastroenterology, 22 (3), 1078-87. 
 34 
Nurgali, Kulmira, et al. (2007), 'Phenotypic changes of morphologically identified guinea-pig 
myenteric neurons following intestinal inflammation', The Journal of Physiology, 583 (Pt 2), 
593-609. 
Nurgali, Kulmira, et al. (2011), 'Morphological and functional changes in guinea-pig neurons 
projecting to the ileal mucosa at early stages after inflammatory damage', The Journal of 
Physiology, 589 (Pt 2), 325-39. 
O’Hara, Ann M., et al. (2006), 'Interleukin-8 Induction by Helicobacter pylori; in Gastric Epithelial 
Cells is Dependent on Apurinic/Apyrimidinic Endonuclease-1/Redox Factor-1', The Journal of 
Immunology, 177 (11), 7990. 
Okuma, Yu, et al. (2012), 'Anti–high mobility group box-1 antibody therapy for traumatic brain 
injury', Annals of Neurology, 72 (3), 373-84. 
Park, J. S., et al. (2004), 'Involvement of toll-like receptors 2 and 4 in cellular activation by high 
mobility group box 1 protein', J Biol Chem, 279 (9), 7370-7. 
Paudel, Yam Nath, et al. (2018), 'HMGB1: A Common Biomarker and Potential Target for TBI, 
Neuroinflammation, Epilepsy, and Cognitive Dysfunction', Frontiers in neuroscience, 12, 628-
28. 
Pines, Alex, et al. (2005), 'Activation of APE1/Ref-1 is dependent on reactive oxygen species 
generated after purinergic receptor stimulation by ATP', Nucleic acids research, 33 (14), 
4379-94. 
Pochard, Camille, et al. (2018), 'The multiple faces of inflammatory enteric glial cells: is Crohn’s 
disease a gliopathy?', American Journal of Physiology-Gastrointestinal and Liver Physiology, 
315 (1), G1-G11. 
Prasad, Rajendra, et al. (2007), 'HMGB1 is a cofactor in mammalian base excision repair', Molecular 
cell, 27 (5), 829-41. 
Prattis S, Jurjus A (2015), 'Spontaneous and transgenic rodent models of inflammatory bowel 
disease'. Lab Anim Res, 31(2), 47-68.Rahman, Ahmed A., et al. (2015), 'Alterations in the 
distal colon innervation in Winnie mouse model of spontaneous chronic colitis', Cell and 
Tissue Research, 362 (3), 497-512. 
Rahman, Ahmed A., et al. (2016), 'Rectal prolapse in Winnie mice with spontaneous chronic colitis: 
changes in intrinsic and extrinsic innervation of the rectum', Cell And Tissue Research, 366 
(2), 285-99. 
Rao, S. S., et al. (1987), 'Studies on the mechanism of bowel disturbance in ulcerative colitis', 
Gastroenterology, 93 (5), 934-40. 
Rezaie A, Parker RD, Abdollahi M (2007), 'Oxidative stress and pathogenesis of inflammatory bowel 
disease: an epiphenomenon or the cause?' Dig Dis Sci 52, 2015–2021. 
Roberts, Jane A., et al. (2013), 'Oxidative stress disrupts purinergic neuromuscular transmission in 
the inflamed colon', The Journal of physiology, 591 (15), 3725-37. 
Roberts, Rachael R., et al. (2007), 'Development of colonic motility in the neonatal mouse-studies 
using spatiotemporal maps', American Journal of Physiology-Gastrointestinal and Liver 
Physiology, 292 (3), G930-G38. 
Roberts, Rachael R., et al. (2008), 'Disturbances of colonic motility in mouse models of 
Hirschsprung's disease', American Journal of Physiology-Gastrointestinal and Liver 
Physiology, 294 (4), G996-G1008. 
Robinson, Ainsley M., et al. (2016), 'Fecal Microbiota and Metabolome in a Mouse Model of 
Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel Disease', 
Inflammatory Bowel Diseases, 22 (12), 2767-87. 
Robinson, Ainsley M., et al. (2017), 'Alterations of colonic function in the Winnie mouse model of 
spontaneous chronic colitis', American Journal of Physiology-Gastrointestinal and Liver 
Physiology, 312 (1), G85-G102. 
Shah, Fenil, et al. (2017), 'Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: 
from bench to clinic', npj Precision Oncology, 1 (1), 19. 
 35 
Shahda, Safi, et al. (2019), 'A phase I study of the APE1 protein inhibitor APX3330 in patients with 
advanced solid tumors', Journal of Clinical Oncology, 37 (15_suppl), 3097-97. 
Swaminathan, Mathusi, et al. (2016), 'Video Imaging and Spatiotemporal Maps to Analyze 
Gastrointestinal Motility in Mice', JoVE,  (108), e53828. 
Tang, Yiting, et al. (2016), 'Regulation of Posttranslational Modifications of HMGB1 During Immune 
Responses', Antioxidants & redox signaling, 24 (12), 620-34. 
Tell, Gianluca, et al. (2009), 'The Many Functions of APE1/Ref-1: Not Only a DNA Repair Enzyme', 
Antioxidants & Redox Signaling, 11 (3), 601-19. 
Tsung, Allan, et al. (2007), 'HMGB1 release induced by liver ischemia involves Toll-like receptor 4–
dependent reactive oxygen species production and calcium-mediated signaling', The Journal 
of Experimental Medicine, 204 (12), 2913. 
Uesaka, Toshihiro, et al. (2016), 'Development of the intrinsic and extrinsic innervation of the gut', 
Developmental Biology, 417 (2), 158-67. 
Vascotto, Carlo, et al. (2009), 'APE1/Ref-1 Interacts with NPM1 within Nucleoli and Plays a Role in 
the rRNA Quality Control Process', Molecular and Cellular Biology, 29 (7), 1834-54. 
Vasko, Michael R., et al. (2011), 'The repair function of the multifunctional DNA repair/redox protein 
APE1 is neuroprotective after ionizing radiation', DNA repair, 10 (9), 942-52. 
Wink, David A., et al. (2011), 'Nitric oxide and redox mechanisms in the immune response', Journal 
of leukocyte biology, 89 (6), 873-91. 
Yang, Xiao, et al. (2018), 'The regulatory role of APE1 in epithelial-to-mesenchymal transition and in 
determining EGFR-TKI responsiveness in non-small-cell lung cancer', Cancer Medicine, 7 (9), 
4406-19. 
Yuk, J. M., et al. (2009), 'A dual regulatory role of apurinic/apyrimidinic endonuclease 1/redox factor-































Neurons Chicken 1:5000 LMMP Abcam 
Anti-GFAP 
(ab53554) 
Glial Cells Goat 1:500 LMMP Abcam 












Mouse 1:500 LMMP Abcam 
Anti-8-OHdG 
(ab48508) 




Figure 1. The effects of APX3330 treatment on clinical symptoms in Winnie mice 
A. Images of a C57BL/6 control mouse and a Winnie sham-treated mouse with severe 
intestinal inflammation and rectal prolapse with blood vessel proliferation and oedema 
before and after 14 days of APX3330 treatment. B, B’. Colons from C57BL/6 control, 
Winnie sham-treated and Winnie APX3330-treated mice were excised and their length 
(mm) measured at day 15 (n=5/group).  C. Faecal water content (the difference 
between the wet and dry weight) was calculated as a percent of the wet weight of fresh 
faecal pellets measured at day 14 of treatment (n=7/group).  D, D’. Gross morphology 
of the distal colon was assessed by H&E staining and histological scoring was 
quantified in distal colon cross sections from C57BL/6 control, Winnie sham-treated 
and Winnie APX3330-treated mice (n=5/group). E. Body weight loss or gain in 
C57BL/6 control (n=10), Winnie sham-treated (n=10) and Winnie APX3330-treated 
(n=8) mice over the 14 day period. Data expressed as mean ± SEM, *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 compared to C57BL/6 control mice; ^P<0.05, 
^^P<0.01 compared to Winnie sham-treated mice. 
 
Figure 2. The anti-inflammatory effects of APX3330 treatment in the colon of 
Winnie mice 
A, A’. CD45+ leukocytes were labelled using a leukocyte marker anti-CD45+ (green) 
antibody in the colon cross sections. Mucosal epithelial cells are labelled with nuclei 
marker DAPI (blue) (A: scale bar = 50µm, x40 magnification; A’: scale bar = 30µm, 
x60 magnification). B. Density of CD45+-IR cells normalised to the width of the colon 
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sections in C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice 
(n=5/group). C. Lipocalin-2 (Lcn-2) levels in faecal pellets were quantified from 
C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice 
(n=5/group). Data expressed as mean ± SEM, **P<0.01, ***P<0.001 compared to 
C57BL/6 control mice; ^^P<0.01 compared to Winnie sham-treated mice. 
 
Figure 3. The effects of APX3330 treatment on gastrointestinal transit 
A-A’’.  Radiographic images captured movement of the contrast agent, barium sulfate, 
from the stomach to the expulsion of the first pellet (shown in red rectangles) in 
C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice 
(n=7/group). B. Overall gastrointestinal transit time extended in Winnie sham-treated 
mice and subsided in Winnie APX3330-treated mice. C. Gastro-caecal transit time 
(GCTT) demonstrated no significant changes between C57BL/6 control, Winnie sham-
treated and Winnie APX3330-treated mice. D. A prolonged caecum retention time was 
observed in Winnie sham-treated mice and was attenuated in Winnie APX3330-
treated mice. E. Colonic transit time (CTT) was accelerated in Winnie sham-treated 
mice and was comparable to C57BL/6 control mice improved in Winnie APX3330-
treated animals. Data expressed as mean ± SEM, **P<0.01 compared to C57BL/6 
control mice; ^P<0.05, ^^P<0.01 compared to Winnie sham-treated mice. 
 
Figure 4. The effects of APX3330 treatment on parameters of colonic motility  
A. Video recordings from ex vivo whole colon samples were transposed into 
spatiotemporal maps. Contractions were distinguished as red and relaxation as blue 
from C57BL/6 control, Winnie sham-treated and Winnie APX3330-treated mice 
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(n=6/group). B. Average length of contractions in proportion to the whole colon length 
C. Average length of colonic migrating motor complexes (CMMCs, white arrows in A) 
defined as contractions initiated from the oral end that propagated toward the anal end 
for >50% of the colon length. D. Speed of propagation of CMMCs. E. Frequency of 
CMMCs quantified as the number of contractions per 10 minutes. Data expressed as 
mean ± SEM, *P<0.05, ****P<0.0001 compared to C57BL/6 control mice; ^P<0.05, 
^^^^P<0.0001 compared to Winnie sham-treated mice.  
 
Figure 5. APX3330 treatment promoted myenteric neuronal survival and 
ameliorated nerve fiber and glial cell density in the myenteric plexus in Winnie 
mice 
A. Neuronal microtubule proteins were labelled by immunofluorescence using -
tubulin (III) (purple) antibody to identify nerve fibers innervating the colon in cross 
sections (scale bar = 100µm, x20 magnification). Anti-MAP2-IR antibody staining 
(blue) for myenteric neurons in LMMP preparations (scale bar = 50µm, x40 
magnification). Glial cells were labelled with an anti-GFAP antibody (orange) in the 
myenteric plexus of the colon from C57BL/6 control, Winnie sham-treated and Winnie 
APX3330-treated mice (scale bar = 50µm, x40 magnification). B. Density of -tubulin 
(III)-IR nerve fibers normalised to colon thickness in C57BL/6 control, Winnie sham-
treated and Winnie APX3330-treated mice (n=5/group). C. Quantitative analysis of 
myenteric neurons per ganglion C57BL/6 control, Winnie sham-treated and Winnie 
APX3330-treated mice (n=5/group). D. Myenteric neurons were quantified per area in 
LMMP preparations of C57BL/6 control, Winnie sham-treated and Winnie APX3330-
treated mice (n=5/group). E.  Density of GFAP-IR glial cells per ganglia in C57BL/6 
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control, Winnie sham-treated and Winnie APX3330-treated mice (n=5/group). Data 
expressed as mean ± SEM, *P<0.05, **P<0.01, ***P<0.001, compared to C57BL/6 
control mice; ^P<0.05, ^^P<0.01, ^^^P<0.001, compared to Winnie sham-treated 
mice. 
 
Figure 6. Effects of APX3330 treatment on superoxide production and HMGB1 
translocation in the myenteric plexus of Winnie mice 
A. LMMP preparations of the distal colon were labelled with Mitochondrial superoxide 
marker MitoSOX (red) indicative of oxidative stress. Increased MitoSOX 
immunofluorescence was evident in the myenteric ganglia of Winnie sham-treated 
(n=5) compared to C57BL/6 control (n=5) mice (scale bar=100µm, x40 magnification). 
This was alleviated in Winnie APX3330-treated (n=5) mice (scale bar=100µm) A’. 
HMGB1 immunoreactivity (green) colocalised with nuclei marker DAPI (blue) in the 
myenteric plexus. Translocation of nuclear HMGB1 to cytosol (marked with white 
arrows) was observed in Winnie sham-treated compared to C57BL/6 control (mice 
and was averted in Winnie APX3330-treated mice (n=5/group) (scale bar=50µm, x60 
magnification). B. MitoSOX fluorescence intensity was assessed relative to ganglion 
area. C. The number of cells with translocation of HMBG1 from nucleus to cytoplasm 
was quantified in the myenteric ganglia. Data expressed as mean ± SEM, *P<0.05, 
**P<0.01 compared to C57BL/6 control mice; ^P<0.05, ^^P<0.01 compared to Winnie 
sham-treated mice.  
 
Figure 7. The effects of APX3330 treatment on APE1/Ref-1 expression in 
myenteric neurons of Winnie mice 
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A. APE1/Ref-1 labelled by immunofluorescence (red) in the colon cross sections.  A’. 
APE1/Ref-1 immunofluorescence (green) in the myenteric plexus in wholemount 
LMMP preparations. B. Density of APE1/Ref-1 fluorescence in the colon cross 
sections relative to the total area of colonic mucosa in C57BL/6, Winnie sham-treated, 
Winnie APX3330-treated mice (n=5/group) (scale bar=100µm, x20 magnification). C. 
Density of APE1/Ref-1 fluorescence quantified as a percentage relative to the 
ganglion area in the myenteric plexus in C57BL/6 control, Winnie sham-treated, 
Winnie APX3330-treated mice (n=5/group) (scale bar=50µm, x40 magnification). Data 
expressed as mean ± SEM, *P<0.05, ****P<0.0001 compared to C57BL/6 control 
mice; ^^^P<0.001 compared to Winnie sham-treated mice. 
Figure 8. The effects of APX3330 treatment on DNA damage in myenteric 
neurons of Winnie mice 
A. DNA damage was observed with an anti-8-OHdG (green) antibody in myenteric 
neurons immunoreactive for MAP2 (purple) (scale bar=50µm, x40 magnification). B. 
The density of 8-OHdG-IR cells was quantified as a percentage relative to the ganglion 
area within myenteric plexus in C57BL/6 control, Winnie sham-treated and Winnie 
APX3330-treated mice (n=5/group). C. The number of neurons with colocalisation of 
8-OHdG-IR and MAP2-IR relative to the total number of neurons per ganglion area. 
Data expressed as mean ± SEM, **P<0.01 compared to C57BL/6 control; ^^P<0.01 
compared to Winnie sham-treated mice.  
 
Figure 9. Effects of APX3330 treatment on enteric neurons and GI functions.  
In the inflamed colon, high levels of colonic leukocyte infiltration and faecal Lcn-2 were 
alleviated by APX3330 treatment. Chronic intestinal inflammation associates with the 
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damage to the enteric nervous system embedded within the intestinal wall and 
controlling gastrointestinal (GI) functions. In enteric neurons, APX3330 treatment 
APX3330 reduces oxidative stress via inhibition of APE1/Ref-1’s redox signalling, 
mitochondrial superoxide production and oxidative DNA damage. On the other hand, 
suppressing APE1/Ref-1 redox activity enhances APE1/Ref-1’s endonuclease repair 
activity.  DNA damage induces translocation of HMGB1 from the nucleus to the 
cytoplasm. Acetylated cytosolic HMGB1 released from cells into extracellular space 
interacts with immune cells and stimulates production of cytokines and chemokines 
leading to neuroinflammation, hyperexcitability and neuronal death (dashed line: not 
studied in our model). After APX3330 treatment HMGB1 was retained in the nuclei of 
myenteric neurons. Targeting this pathway with APX3330 ameliorated enteric 
neuropathy, colonic dysmotility and altered GI transit leading to improved clinical signs 
associated with chronic colitis (created with BioRender.com). 
 
 
